TScan Therapeutics, Inc. (TCRX) - Q2 2024 10-Q Summary
Business Context and Reporting Period
TScan Therapeutics, Inc. is a clinical-stage biotechnology company developing T cell receptor (TCR)-engineered T cell (TCR-T) therapies for hematologic and solid tumor malignancies. This report covers the quarterly period ended June 30, 2024. The Company is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Revenue | $536 | $3,148 | $1,102 | $9,951 |
| Net Loss | $(31,661) | $(24,045) | $(61,803) | $(46,608) |
| Net Loss Per Share (Basic/Diluted) | $(0.28) | $(0.51) | $(0.59) | $(1.30) |
| Operating Expenses | $34,650 | $27,758 | $66,589 | $57,304 |
| Cash, Cash Equivalents & Marketable Securities | $297,676 | $192,044 | $297,676 | $192,044 |
| Accumulated Deficit | $(309,400) | $(204,987) | $(309,400) | $(204,987) |
Note: Cash, Cash Equivalents & Marketable Securities calculated as Cash ($242,159) + Marketable Securities ($55,517). Restricted cash of $5,031 is excluded from this liquidity metric but included in total cash balances.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased significantly year-over-year (Q2 2024: $0.5M vs. Q2 2023: $3.1M). This is primarily due to the timing of research activities under the Amgen collaboration agreement, which commenced in May 2023, and the conclusion of the Novartis agreement in March 2023.
- Increased Operating Expenses: Total operating expenses rose by $6.9M in Q2 2024 compared to Q2 2023.
- R&D Expenses: Increased by $5.7M, driven by a $2.6M increase in clinical studies (enrollment in the ALLOHA Phase 1 heme trial and solid tumor trials) and a $1.9M increase in personnel expenses.
- G&A Expenses: Increased by $1.2M, primarily due to higher personnel costs.
- Capital Raising: In April 2024, the Company completed an underwritten public offering, raising approximately $161.4 million in net proceeds through the sale of common stock and pre-funded warrants. This significantly bolstered liquidity compared to the prior year.
- Debt Status: The Company has a $30 million convertible term loan from K2 HealthVentures LLC. The option to draw a second tranche of $10 million expired on June 1, 2024. The current interest rate is 9.90%.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes existing cash, cash equivalents, and marketable securities ($297.7 million as of June 30, 2024) are sufficient to fund operations into the fourth quarter of 2026.
- Development Progress:
- Heme Program: The ALLOHA Phase 1 "umbrella" trial for TSC-100 and TSC-101 is ongoing with over ten clinical sites activated.
- Solid Tumor Program: Six TCR-T candidates have advanced to Phase 1. The FDA has cleared the IND for T-Plex, enabling multiplex TCR-T therapy trials.
- Regulatory Designations: In May 2024, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for TSC-100 and TSC-101 for specific leukemia and MDS indications.
- Key Risks:
- Capital Requirements: The Company expects to incur significant losses for the foreseeable future and will require substantial additional funding to complete development and commercialization.
- Development Risks: Clinical trials may fail to demonstrate safety or efficacy; manufacturing complexities for cell therapies pose scaling challenges.
- Collaboration Dependence: Revenue is currently dependent on collaboration agreements (e.g., Amgen). Future revenue is uncertain until product approval.
- Debt Covenants: The loan agreement requires maintaining minimum unrestricted cash equal to 5.0 times the average monthly cash burn.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "fourth quarter of 2026" funding estimate against current burn rates and potential delays in clinical milestones.
- Amgen Revenue Recognition: Review the specific terms of the Amgen collaboration to understand the timing of future revenue recognition and the probability of achieving the $500M+ in potential milestones.
- Clinical Trial Enrollment: Monitor patient enrollment rates for the ALLOHA trial and solid tumor programs, as delays here directly impact cash burn and future funding needs.
- Debt Conversion Terms: Assess the dilution impact of the K2HV convertible loan (conversion price $4.785) and the potential for the lender to convert debt to equity.
- Manufacturing Scalability: Evaluate the Company's progress in validating its internal manufacturing facility versus reliance on third-party manufacturers for pivotal trials.